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Summary
 
The costimulatory molecules B7-1 and B7-2 regulate T lymphocyte activation by delivering
activating signals through CD28 and inhibitory signals through cytotoxic T lymphocyte–asso-
ciated antigen 4 (CTLA-4). The importance of CTLA-4–mediated inhibition was demon-
strated by the uncontrolled T cell activation and lymphoproliferative disease that develops in
CTLA-4–deficient (
 
2
 
/
 
2
 
) mice. To examine the role of B7 signaling in the activation of
CTLA-4–deficient T cells, we bred CTLA-4
 
2
 
/
 
2
 
 mice with mice lacking B7-1, B7-2, or both
B7 molecules. The CTLA-4/B7-1
 
2
 
/
 
2
 
 and the CTLA-4/B7-2
 
2
 
/
 
2
 
 mice develop lymphoprolif-
eration and enhanced T cell activation. Mice lacking CTLA-4, B7-1, and B7-2 have a normal
life-span, and do not have lymphocytic infiltrates in any organs, or increased T cell activation.
Therefore, the two B7 molecules have overlapping functions, since either B7-1 or B7-2 alone
can cause the CTLA-4
 
2
 
/
 
2
 
 phenotype. Elimination of both B7-1 and B7-2 from the CTLA-4–
deficient mouse abrogates the lymphocyte activation and disease, and does not reveal evidence
for additional stimulatory CD28 ligands. The CTLA-4
 
2
 
/
 
2
 
 phenotype can be reproduced with
anti-CD28 antibody in mice lacking CTLA-4, B7-1, and B7-2, but wild-type mice are unaf-
fected by the same treatment. This suggests that the inhibitory function of CTLA-4 can over-
come strong CD28-mediated signaling in vivo.
Key words: cytotoxic T lymphocyte–associated antigen 4 • B7 • knockout mouse • 
costimulation • T lymphocyte
 
T
 
he importance of the B7-CD28/cytotoxic T lym-
phocyte–associated antigen 4 (CTLA-4) pathway has
been highlighted by studies showing that blockade of B7
costimulation can prolong allograft survival (1) and suppress
autoimmunity (2). The two B7 ligands, B7-1 (CD80) and
B7-2 (CD86), can both stimulate immune responses by
binding to CD28 and downregulate responses by binding
to CTLA-4. Because B7-2 is expressed constitutively and
upregulated earlier than B7-1, it has been suggested that
B7-2 participates in initiating an immune response, whereas
B7-1 may be more important in sustaining or regulating
ongoing responses. The upregulation of CTLA-4 on acti-
vated T cells parallels the kinetics of B7-1 expression. To-
gether with the higher avidities of B7 ligands for CTLA-4
than CD28, this has raised the possibility that B7-1/CTLA-4
interactions predominate late to terminate immune responses.
However, several reports suggest that B7-1 and B7-2 can
provide similar signals (3, 4). Further understanding of the
complexities in this pathway is required in order to optimize
therapies that target this pathway.
To study the interactions between receptors and ligands
in the B7-CD28/CTLA-4 pathway, we have generated
and characterized mice lacking expression of one or more
molecules in the pathway. The phenotype of mice lacking
CTLA-4 (CTLA-4
 
2
 
/
 
2
 
) provides crucial evidence that
CTLA-4 plays a negative regulatory role in T cell activa-
tion. These mice develop a fatal lymphoproliferative disease
with lymphocytic infiltrates in multiple organs (5, 6).
CTLA-4
 
2
 
/
 
2
 
 T cells are highly activated in vivo and spon-
taneously proliferate in vitro without any added stimuli.
Early treatment with CTLA4Ig blocks the T cell activation
and lymphoproliferation, demonstrating that B7, presum-
ably functioning by ligating CD28, is necessary for the de-
velopment of the CTLA-4
 
2
 
/
 
2
 
 phenotype (7). However,
these studies do not address whether CD28 interacts only
with B7-1 and B7-2, or if additional ligands for CD28/
CTLA-4 exist, as some have proposed (8, 9). The T cell
activation observed in CTLA-4
 
2
 
/
 
2
 
 mice and its depen-
dence on B7 molecules provide a unique system for ex-
ploring interactions in this pathway. 
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Here we have used the CTLA-4
 
2
 
/
 
2
 
 mouse as a tool to
investigate interactions between CD28 and its ligands. We
have generated and characterized three novel mouse strains,
which are CTLA-4–deficient and also lack B7-1, B7-2,
or both B7 molecules. If additional stimulatory CD28 li-
gands existed, then mice lacking CTLA-4, B7-1, and B7-2
would be expected to develop increased T cell activation.
Alternatively, if there is not increased T cell activation in
these mice, then this would suggest that in the absence of
the two known B7 molecules, CD28 is no longer engaged.
We found that mice lacking CTLA-4 and either B7-1 or
B7-2 develop the lymphoproliferative phenotype observed
in the CTLA-4
 
2
 
/
 
2
 
 strain, but that mice deficient in
CTLA-4 and B7-1 have a shorter life-span and show
greater T cell activation in vivo than the CTLA-4/B7-2–
deficient mice. In contrast, mice lacking CTLA-4, B7-1,
and B7-2 (“triple knockout,” CTLA-4/B7-1/B7-2
 
2
 
/
 
2
 
 TKO)
show no evidence of T cell activation or lymphopro-
liferation, suggesting that there are no additional stimula-
tory ligands for CD28. We also show that administration
of anti-CD28 antibody to CTLA-4/B7-1/B7-2
 
2
 
/
 
2
 
 TKO
mice can reproduce the phenotype of the CTLA-4
 
2
 
/
 
2
 
mouse, demonstrating the critical role of CD28 in activat-
ing CTLA-4
 
2
 
/
 
2
 
 T cells.
 
Materials and Methods
 
Mice.
 
Mouse strains lacking CTLA-4 (6), B7-1 (10), B7-2, or
both B7 molecules (11) have been described previously. Because
CTLA-4–deficient mice die before reaching sexual maturity, the
three CTLA-4/B7–deficient mice were generated by interbreed-
ing CTLA-4 heterozygotes with B7-1–, B7-2–, or B7-1/B7-2-
deficient mice. Mice heterozygous for both CTLA-4 and the B7
mutation were then intercrossed, and CTLA-4/B7–deficient mice
were obtained. Because of the lethality of the CTLA-4/B7-1–
and CTLA-4/B7-2–deficient phenotypes, these two strains were
maintained by interbreeding CTLA-4
 
1
 
/
 
2
 
/B7
 
2
 
/
 
2
 
 mice. The
CTLA-4/B7-1/B7-2
 
2
 
/
 
2
 
 TKO strain survives to adulthood, and
was maintained by interbreeding these mice. All strains were ge-
notyped by Southern blots, as described previously for CTLA-4
(6), B7-1 (10), and B7-2 (11). Genotypes were confirmed by flow
cytometric analysis of splenocytes stimulated with LPS 20 
 
m
 
g/ml
and dextran sulfate 10 
 
m
 
g/ml for expression of B7 molecules, and
splenocytes stimulated with anti-CD3 (mAb 145-2C11) for ex-
pression of CTLA-4. All mice were generated on an inbred 129/
SvJae background. Brigham and Women’s Hospital and Harvard
Medical School are accredited by the American Association of
Accreditation of Laboratory Animal Care (AALAC), and mice
were cared for in accordance with institutional guidelines in a
pathogen-free animal facility.
 
In Vivo Administration of Anti-CD28.
 
Wild-type and CTLA-
4/B7-1/B7-2
 
2
 
/
 
2
 
 TKO mice received either PV-1 mAb to
CD28, provided by Dr. Vijay K. Kuchroo (Brigham and
Women’s Hospital), or hamster IgG (ICN Pharmaceuticals). 100
 
m
 
g i.v. of purified antibody was administered on days 0, 7, and
14, and mice were analyzed between days 14 and 19.
 
Cell Preparation and Cultures.
 
Single cell suspensions from
spleen and lymph nodes were prepared by dissociating tissue with
sterile glass slides. Red blood cells were lysed by incubation in
Tris-ammonium chloride for 5 min at 37
 
8
 
C. To assay prolifera-
tion, 2 
 
3 
 
10
 
5
 
 cells/well were cultured in flat-bottomed 96-well
plates in media as described previously (6). Cells were pulsed with
1 
 
m
 
Ci [
 
3
 
H]thymidine for the last 8 h of the indicated day. Anti-
CD3 stimulation used high titer supernatant prepared from the
145-2C11 hybridoma, obtained from the American Type Cul-
ture Collection.
 
Cell Surface Staining.
 
Spleen and lymph node cells were
stained with fluorochrome-conjugated mAbs including anti–
CTLA-4 (4F10), anti–B7-1 (1G10), anti–B7-2 (GL1), anti-
CD62L (Mel 14), anti-CD69 (H1.2F3), anti-CD25 (7D4), and
anti-CD3 (145-2C11). These antibodies were purchased from
PharMingen. Stained cells were analyzed on a FACSCalibur
 
®
 
(Becton Dickinson).
 
Histology.
 
Tissue for light microscopy was fixed in 10% buff-
ered formalin, embedded in paraffin, sectioned, and stained with
hematoxylin and eosin using standard techniques.
 
Results
 
B7-1– or B7-2–mediated Signals Are Required to Produce
Lymphoproliferation and Fatal Disease in the CTLA-4–deficient
Mouse.
 
To assess the role of B7-1 and B7-2 in producing
lymphoproliferative disease in mice lacking CTLA-4, we
crossed the CTLA-4–deficient strain with mice lacking
B7-1, B7-2, or both B7 molecules. Mice lacking CTLA-4
and B7-1 (CTLA-4/B7-1
 
2
 
/
 
2
 
) and mice lacking CTLA-4
and B7-2 (CTLA-4/B7-2
 
2
 
/
 
2
 
) develop the characteristic fa-
tal phenotype of CTLA-4
 
2
 
/
 
2
 
 mice. The survival of the
CTLA-4/B7-1
 
2
 
/
 
2
 
 mice (mean 
 
5 
 
21.9 d;
 
 n 
 
5 
 
8) was
shorter than that of the CTLA-4/B7-2
 
2
 
/
 
2
 
 mice (mean 
 
5
 
30.5 d;
 
 n 
 
5 
 
8) (
 
P
 
 
 
5 
 
0.02 by Wilcoxon signed rank test).
The difference in survival between the CTLA-4/B7-1
 
2
 
/
 
2
 
and the CTLA-4
 
2
 
/
 
2
 
 (mean
 
 5 
 
17.5 d;
 
 n 
 
5 
 
11) strains did
not reach statistical significance (
 
P
 
 . 
 
0.05; Fig. 1). In con-
trast, CTLA-4/B7-1/B7-2
 
2
 
/
 
2
 
 TKO mice lacking CTLA-4,
Figure 1. Either B7-1– or B7-2–mediated signaling is sufficient to pro-
duce fatal lymphoproliferative disease in mice lacking CTLA-4. Mice
were observed daily, and survival was recorded. Survival of CTLA-42/2,
CTLA-4/B7-12/2, and CTLA-4/B7-22/2 strains is shown. Each mouse
is indicated by a different symbol, and mean life-span is shown as a hori-
zontal bar. Wild-type and CTLA-4/B7-1/B7-22/2 TKO mice consis-
tently live longer than 300 d. 
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B7-1, and B7-2 remain healthy and have a life-span and re-
productive capacity comparable to wild-type mice.
Both the CTLA-4/B7-1
 
2
 
/
 
2
 
 and CTLA-4/B7-2
 
2
 
/
 
2
 
strains develop splenomegaly, lymphadenopathy, and mul-
tiorgan lymphocytic infiltrates with tissue damage, similar
to the CTLA-4
 
2
 
/
 
2
 
 mice. The CTLA-4/B7-1
 
2
 
/
 
2
 
 mice
typically develop these pathologic changes earlier than the
CTLA-4/B7-2
 
2
 
/
 
2
 
 mice. In contrast, CTLA-4/B7-1/B7-
2
 
2
 
/
 
2
 
 TKO mice develop neither splenomegaly nor lymph-
adenopathy. Detailed histologic examination of CTLA-4/
B7-1/B7-2
 
2
 
/
 
2
 
 TKO mice ranging in age from 2 to 8 mo re-
veals the complete absence of lymphocytic infiltrates (Fig.
2). These results indicate that either B7-1 or B7-2 can pro-
vide the necessary activating signal for the lymphoprolifera-
tive phenotype in CTLA-4
 
2
 
/
 
2
 
 mice, but that the absence
of both B7 molecules abrogates the phenotype.
 
In the Absence of CTLA-4, Extensive T Cell Activation Oc-
curs Only in the Presence of B7-1 or B7-2.
 
To assess the de-
gree of T cell activation in these mouse strains in vivo,
freshly isolated splenocytes were stained for activation
markers and analyzed by flow cytometry. T cells from
CTLA-4
 
2
 
/
 
2
 
, CTLA-4/B7-1
 
2
 
/
 
2
 
, and CTLA-4/B7-2
 
2
 
/
 
2
 
mice show significant increases in the percentage that are
positive for the activation marker CD69 (Fig. 3) and
CD62L-low (data not shown) compared with wild-type
mice. In four animals of each strain analyzed at 2 wk, there
was a mean of 51% CD69
 
1
 
 T cells in CTLA-4
 
2
 
/
 
2
 
, 48% in
CTLA-4/B7-1
 
2
 
/
 
2
 
, and 44% in CTLA-4/B7-2
 
2
 
/
 
2
 
 mice.
The same trend was observed when staining for CD62L,
but the differences did not reach statistical significance. In
contrast, 
 
,
 
10% of CTLA-4/B7-1/B7-2
 
2
 
/
 
2 TKO cells are
activated, as assessed by staining for CD69 (Fig. 3) and
CD62L (data not shown). None of the CTLA-4/B7-1/
B7-22/2 TKO mice analyzed show significant T cell acti-
vation. Both the CTLA-4/B7-1/B7-22/2 TKO and B7-1/
B7-22/2 strains have consistently fewer activated T cells
than wild-type mice.
We have previously reported that unfractionated spleno-
cytes from CTLA-42/2 mice proliferate spontaneously in
vitro in the absence of exogenous stimulation (7). This as-
say serves as another measure of unopposed T cell activa-
tion in CTLA-42/2 mice. Proliferation in both CTLA-4/
B7-12/2 and CTLA-4/B7-22/2 strains was significantly
higher than in wild-type mice (Fig. 4 A). As might be ex-
pected from other measures of T cell activation in the two
strains, CTLA-4/B7-12/2 cells proliferate more than those
from age-matched CTLA-4/B7-22/2 cells. In contrast,
CTLA-4/B7-1/B7-22/2 TKO splenocytes do not prolifer-
ate spontaneously, suggesting that no CD28 signaling oc-
curs in the absence of B7-1 and B7-2.
Figure 2. Removal of B7-1–
and B7-2–mediated signaling
prevents the lymphocytic infiltra-
tion and necrosis of organs ob-
served in CTLA-42/2 mice.
Heart (A, B, and C) and pancreas
(D, E, and F) are shown (original
magnification: 350). CTLA-42/2
mice (B and E), as well as
CTLA-4/B7-12/2 and CTLA-
4/B7-22/2 mice (not shown),
killed at 2 wk of age show severe
pancreatitis and myocarditis, in
contrast to wild-type littermates
(A and D). CTLA-4/B7-1/B7-
22/2 TKO mice killed at 2 mo
show no evidence of inflamma-
tory infiltrates (C and F).438 Role of B7 Molecules in Activation of CTLA-4–deficient T Cells
We also assessed the in vitro proliferative response of
CTLA-4/B7-1/B7-22/2 TKO T cells to anti-CD3 anti-
body stimulation. The response of CTLA-4/B7-1/B7-22/2
TKO splenocytes is markedly reduced compared with
wild-type mice (Fig. 4 B). This deficit is indistinguishable
from that observed with the B7-1/B7-22/2 mice. Spleno-
cytes from CTLA-42/2, CTLA-4/B7-12/2, and CTLA-4/
B7-22/2 mice which are already activated in vivo showed a
proliferative response to anti-CD3 stimulation that was
highly variable between experiments, presumably because
of varying numbers of in vivo–activated T cells, which un-
dergo activation-induced cell death upon restimulation in
vitro.
In Vivo Administration of Anti-CD28 to CTLA-4/B7-1/
B7-22/2 TKO Mice Activates T Cells and Produces Fatal Lym-
phoproliferative Disease. The results showing that T cell ac-
tivation in CTLA-42/2 mice requires B7-1 or B7-2 suggest
that B7–CD28 interactions are critical for such activation.
If CD28 signaling is sufficient to cause T cell activation in
the absence of CTLA-4, then ligating CD28 artificially using
anti-CD28 antibody should induce disease in CTLA-4/
B7-1/B7-22/2 TKO mice. To test this, we administered
anti-CD28 mAb (PV-1) to adult mice for 2 wk. Mice were
analyzed 14–19 d after initial treatment with anti-CD28
because they exhibited features typical of the CTLA-42/2
lymphoproliferative disease. At this time, they developed
splenomegaly and lymphadenopathy, with greater than six-
fold increases in cell numbers compared with anti-CD28–
treated wild-type mice (data not shown). CTLA-4/B7-1/
B7-22/2 TKO mice treated with anti-CD28 also developed
lymphocytic infiltrates and necrosis, in an organ distribu-
tion and severity comparable to the CTLA-42/2 mice (data
not shown). No lymphoid or other organ involvement was
observed in CTLA-4/B7-1/B7-22/2 TKO mice receiving
control IgG, or wild-type mice receiving anti-CD28 or
control IgG. Anti-CD28 administration also markedly in-
creased the fraction of activated T cells in the CTLA-4/B7-1/
B7-22/2 TKO mice compared with wild-type, as deter-
mined by CD69 (Fig. 5) and CD62L expression (data not
shown). Thus, signaling through CD28 in the CTLA-4/
B7-1/B7-22/2 TKO strain can reproduce the lymphopro-
liferative disease typical of CTLA-42/2 mice. The lack of ef-
fect of anti-CD28 antibody in wild-type mice in vivo is also
noteworthy, demonstrating that engagement of CTLA-4
Figure 3. In the absence of CTLA-4, in vivo
T cell activation requires B7-1 or B7-2. Sple-
nocytes were isolated from 2-wk-old mice and
double stained with PE–anti-CD3 and FITC–
anti-CD69 for analysis by flow cytometry. The
percentage shown next to each dot plot indi-
cates the proportion of CD31 cells that are
CD691. Results are representative of five mice
of each strain.
Figure 4. Proliferation of CTLA-
42/2 T cells requires B7-1– or B7-2–
mediated costimulation. (A) Prolif-
erative responses of unstimulated
splenocytes from 2-wk-old mice of
the indicated strain at 24 h are shown.
Data are representative of three ex-
periments, and the mean of two mice
of each strain are shown. (B) Prolifer-
ative responses of anti-CD3-stimu-
lated splenocytes from 2-mo-old
mice at 48 h are shown. Data are
representative of four experiments.
The mean of two mice of each strain
are  shown. Proliferation at all time
points was assayed in triplicate, with
SD , 15% of the mean.439 Mandelbrot et al. Brief Definitive Report
by endogenous levels of B7 can inhibit the proliferation of
T cells receiving a strong positive signal through CD28.
Discussion
The dual specificities of B7-1 and B7-2 for CD28 and
CTLA-4 have made it challenging to elucidate physiologi-
cal interactions in the B7-CD28/CTLA-4 pathway. The
uncontrolled T cell activation seen in the CTLA-42/2
mice provides a valuable experimental system for dissecting
in vivo functions of B7-1 and B7-2, and for searching for
additional members of this family of costimulators. To do
this, we have generated mouse strains lacking CTLA-4 and
either B7-1, B7-2, or both B7 molecules, and analyzed
them for evidence of T cell activation in vivo and in vitro.
The phenotypes of the CTLA-4/B7-12/2 and CTLA-4/
B7-22/2 strains demonstrate overlapping roles for B7-1
and B7-2 in CD28-mediated signaling, as the presence of
either B7-1 or B7-2 is sufficient to produce the CTLA-42/2
phenotype. However, the CTLA-4/B7-12/2 mice have
shorter survival and greater T cell activation than age-
matched CTLA-4/B7-22/2 mice. These differences may
reflect earlier expression and higher cell surface levels of
B7-2 compared with B7-1. Since either B7 molecule is ca-
pable of producing lymphoproliferation and T cell activation
in the CTLA-42/2 mice, it seems unlikely that B7-1 and
B7-2 produce fundamentally different signals through CD28.
The striking absence of T cell activation in the CTLA-4/
B7-1/B7-22/2 TKO strain demonstrates that B7-1 or B7-2
is required to produce the CTLA-42/2 lymphoproliferative
disease. The absence of CD28-mediated costimulation in
the CTLA-4/B7-1/B7-22/2 TKO strain is demonstrated
by the (a) lack of lymphoproliferation in vivo, as evidenced
by the normal life-span and absence of splenomegaly, lymph-
adenopathy, and lymphocytic infiltrates; (b) naive pheno-
type of T cells in vivo; (c) lack of spontaneous proliferation
of splenocytes in vitro; and (d) impaired proliferative re-
sponse to CD3 stimulation in vitro. Similar results have
been obtained by treating CTLA-42/2 mice with CTLA4Ig.
Our results extend these studies and show that B7-1 or
B7-2 is capable of activating CTLA-42/2 T cells.
This requirement for B7-1 or B7-2 in activating CTLA-
42/2 T cells is most consistent with a role of unopposed
signaling by CD28, the only known activating T cell recep-
tor for B7 molecules. We have formally established this by
showing that anti-CD28 antibody can reproduce disease in
CTLA-4/B7-1/B7-22/2 TKO mice. Interestingly, the
same anti-CD28 antibody has no detectable effect on T cell
activation in wild-type mice in vivo. These findings dem-
onstrate the critical balance between CD28-mediated T
cell activation and CTLA-4–mediated downregulation, and
suggest that the inhibitory function of CTLA-4 can over-
come strong CD28-mediated signals in vivo. These results
may explain why many studies show no or inconsistent in
vivo effects of anti-CD28 antibodies, which are known to
be strong agonists when added to T cells in the absence of
APCs in vitro.
We have not found evidence for additional stimulatory
CD28 ligands in the CTLA-4/B7-1/B7-22/2 TKO mice.
This strain provides an exquisitely sensitive means for ex-
amining whether additional stimulatory CD28 counter-
receptors exist, since in the absence of CTLA-4, even the
effects of weak CD28-mediated signaling would be appar-
ent. The profound deficits observed in the CTLA-4/B7-1/
B7-22/2 TKO mice would suggest that if additional B7
ligands exist, they either do not stimulate T cell activation
through CD28, or they are expressed in a restricted mi-
croenvironment. Such microenvironments might include
organs such as the brain or kidney, which exhibit no in-
flammatory changes in CTLA-42/2 mice.
The CTLA-4/B7-1/B7-22/2 TKO strain has a pheno-
type that appears to be comparable to the B7-1/B7-22/2
strain both in vivo and in vitro. Therefore, in the absence
of B7-1 and B7-2, the presence of CTLA-4 has no de-
tectable downregulatory effect. Because T cells from the
CTLA-4/B7-1/B7-22/2 TKO strain are mostly naive, un-
like cells from CTLA-42/2 mice, CTLA-4/B7-1/B7-22/2
TKO mice also can serve as a useful tool to study the func-
tion of CTLA-4 during the initial activation of T cells.
We thank Abul Abbas for careful review of the manuscript, Vijay K. Kuchroo for the gift of anti-CD28
antibody, Frank Borriello and Elizabeth A. Tivol for initiating mouse breeding, and Sumi Scott for technical
assistance.
Figure 5. Administration of anti-CD28 antibody to CTLA-4/B7-1/
B7-22/2 TKO mice activates T cells. CTLA-4/B7-1/B7-22/2 TKO and
wild-type mice received either anti-CD28 or control hamster IgG. At
days 14–19, freshly isolated splenocytes were stained for CD3 and the ac-
tivation marker CD69, and analyzed by flow cytometry. The percentage
shown next to each dot plot indicates the proportion of CD31 cells that
are CD691. Data are representative of at least three mice of each strain.440 Role of B7 Molecules in Activation of CTLA-4–deficient T Cells
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